There is muted reaction as the US fiscal cliff has many people cautious. The cancer journal posting is recent, the FDA approval for MTC was recent and now the drug is commercially available in the US and can be used off label. The posting also announces to the oncology community the benefits of cabo and encourages any needy patients consider the available trials.
If patients can't make or qualify for a trial and based off the recent US court case, doctors now have another drug available to them both for MTC and off label use. The market does not realize all the information of the trial nor is it old news. The oncology journal would not have published the information if it were not warranted and valued. Bit by bit information known will expand, trials will continue and the use of cabo will grow.
Triggers coming up will be sales figures of cabo. More news articles. More press releases.
Also, as to the article, there are all sorts of scientists involved supporting the information.
As to the fiscal cliff, the trigger there is very soon the US government will come to a resolution as both parties will want to avert disaster. That will trigger a rise of all stocks to a big jump including Exel.